Nektar Therapeutics (NKTR)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $2.29B
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Latest financial period: June 30, 2026
Filed with the SEC: August 14, 2026
Estimated earnings date: November 5, 2026
Profit #1435 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 2.3% | 2.2% | 1.2% | 1.7% |
Growth #1438 of 1484 companies
Payout #1117 of 1484 companies
Safety #1161 of 1484 companies
Price #1445 of 1484 companies
